iSpecimen Names Chief Financial Officer, Tracy Curley, Interim CEO
23 September 2022 - 6:15AM
iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”),
an online global marketplace that connects scientists in need of
biospecimens for medical research with a network of healthcare
specimen providers, announced today the immediate appointment of
Tracy Curley as interim CEO, replacing current Chief Executive
Officer and President, Christopher Ianelli. In addition to serving
as interim CEO, Ms. Curley will remain CFO. The Board of Directors
(the “Board”) is currently reviewing the Company’s near- and
long-term needs pertaining to the role of Chief Executive Officer.
On September 19, 2022, Dr. Ianelli gave the Board a notice of
departure to vacate his positions as Chief Executive Officer and
President, effective October 24, 2022, as a result of the
non-renewal of his Executive Employment Agreement dated June 21,
2021. Pursuant to the mutual agreement of Dr. Ianelli and the
Board, Dr. Ianelli vacated his positions as Chief Executive Officer
and President on September 21, 2022.
On September 20, 2022, Jill Mullan gave the Board a notice of
departure to vacate her position as Chief Operating Officer,
effective October 24, 2022, as a result of the non-renewal of her
Executive Employment Agreement dated June 21, 2021.
In order to assure a smooth transition, Dr. Ianelli and Ms.
Mullan have both offered and agreed to continue to provide services
as employees of iSpecimen through the termination of their
employment with the Company on October 24, 2022. The Company is
currently negotiating Separation Agreements with each of Dr.
Ianelli and Ms. Mullan, which are expected to include the financial
and other terms of each of their terminations as executive officers
of the Company.
“First, allow me to extend our appreciation to Chris and Jill
for their vision, guidance, and support. At the same time, I want
to thank the current leadership team and everyone at iSpecimen for
their dedication to achieving excellence. I also wish to convey the
confidence the Board and I have in the team’s ability to
successfully operate the business without missing a beat,” said Ms.
Curley, Chief Financial Officer and interim-CEO. “We currently have
several business initiatives underway that, over time, will further
strengthen our leadership position and be transformational in the
biospecimen procurement industry. Our business and balance sheet
are strong, which is especially important during the current
macroeconomic environment. Let us not forget the vital role
iSpecimen serves in advancing breakthrough science and saving
lives.”
About iSpecimen
iSpecimen (Nasdaq: ISPC) offers an online marketplace for human
biospecimens, connecting scientists in commercial and non-profit
organizations with healthcare providers that have access to
patients and specimens needed for medical discovery. Proprietary,
cloud-based technology enables scientists to intuitively search for
specimens and patients across a federated partner network of
hospitals, labs, biobanks, blood centers and other healthcare
organizations. For more information, please
visit www.ispecimen.com.Forward Looking
Statements
This press release may contain forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. Such forward-looking statements are characterized by
future or conditional verbs such as "may," "will," "expect,"
"intend," "anticipate," "believe," "estimate" and "continue" or
similar words. You should read statements that contain these words
carefully because they discuss future expectations and plans, which
contain projections of future results of operations or financial
condition or state other forward-looking information.
Forward-looking statements are predictions, projections and
other statements about future events that are based on current
expectations and assumptions and, as a result, are subject to risks
and uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this press
release, including but not limited to the risks factors contained
in the Company's filings with the Securities and Exchange
Commission, which are available for review at www.sec.gov.
Forward-looking statements speak only as of the date they are made.
New risks and uncertainties arise over time, and it is not possible
for the Company to predict those events or how they may affect the
Company. If a change to the events and circumstances reflected in
the Company's forward-looking statements occurs, the Company's
business, financial condition and operating results may vary
materially from those expressed in the Company's forward-looking
statements.
Readers are cautioned not to put undue reliance on
forward-looking statements, and the Company assumes no obligation
and do not intend to update or revise these forward-looking
statements, whether as a result of new information, future events
or otherwise.
For further information, please contact:
Investor ContactKCSA Strategic
CommunicationsAllison SossiSpecimen@kcsa.com
Media ContactKCSA Strategic
CommunicationsRaquel ConaiSpecimen@kcsa.com
iSpecimen (NASDAQ:ISPC)
Historical Stock Chart
From Apr 2024 to May 2024
iSpecimen (NASDAQ:ISPC)
Historical Stock Chart
From May 2023 to May 2024